Mission

Through our diverse team & dedication to quality, utR Biotech is focused on pure, affordable, efficacious therapeutics.

We have the knowledge and experience to take a target from conception to licensure.

Vision

Our vision is to be a company with a global presence that positively impacts the lives of people with chronic or lifelong illnesses, helping them to live a longer, fuller live with the ability to afford the treatments they will need while delaying, reducing, or eliminating disease complications.

We will drive research forward to marketable products with the goal of being profitable, ethical, sustainable & to contribute to science in a meaningful way.
utR Biotech Currently

utR Biotech is working towards:

- A human & veterinary insulin product that is combined with a peptide showing promise to reduce, delay or eliminate a wide variety of diabetes related complications
- A refinement in how insulin is manufactured that will reduce the cost of insulin for end users by better meeting demand & significantly lowering production costs
- An insulin with a 12-24 month shelf life, far exceeding what is currently available
- A sublingual delivery system for insulin/peptide combination
utR Biotech is actively seeking funding in the form of grants & investors to research a peptide that has been shown to have an effect on a variety of systems & biological processes in the body. The peptide is naturally present in non-diabetics but is not present in Type 1 Diabetics.

The goal will be to bring this product to from development to market as a stand alone additive, licensed or as an insulin/peptide combination.

We believe, after compiling information from over 200 papers, that there is a significant opportunity to produce this peptide and include it with insulin formulations in order to reduce, eliminate or delay the onset of: retinopathy, neuropathy, circulation complications, cardiovascular disease, cancer, Alzheimer’s Disease, liver disease, and other Type 1 Diabetes related complications.
utR Biotech Readiness

- utR Biotech was founded in September 2016 & incorporated in July of 2019, trademarked in USA
- Branding, Website/Social Media live in 2019
- We have engaged MITACS for matched funding for research
- Several world class researchers have signed NDA’s & confirmed interest in advancing our science
- We have initial quotes for work with a large, high quality, CMO in Europe to manufacture our research, pre-clinical and clinical trial materials beyond the concept studies

Our current needs for 2019-2022 are for 2.5 million USD in investment or grants for research leading to patent applications (MITACS to match 1.2x funding for wages and consumables)
Our Executive Team

David Petch M.Sc. – CEO/CSO, Founder

Mr. Petch has over 25 years in the Biotech industry, ranging from Cell Culture, bioassay development, protein purification, product development & hyper-immune processes. His specialty in Cell Culture/fermentation processes and work identifying disruptable markets was the spark for the formation of this company. Mr. Petch has run a stock market information website & published peer reviewed papers on stock market analysis as a hobby. Found a future clinical research scientist to join once concept studies are complete...four other potential candidates found to date.

Mr. Petch serves as CEO and CSO for our company. His vision, knowledge, determination and drive bring focus and direction to our research team. David has been instrumental in compiling the science and attracting interest from top Canadian Scientists, and CMO’s to utR Biotech.

Lyle Kirchner – VP Sales and Marketing, Founder

Mr. Kirchner is a Canadian entrepreneur who has 26 years experience in owning and running his own businesses. His company, Business Information & Development currently provides technology consulting services, website and software design, hosting & email services, & Information Technology supports to over 100 small & medium businesses in Canada. Mr. Kirchner has extensive management experience having owned and run retail stores, service companies and a communication company. He has worked for several “Top 50 Managed Canadian Companies”.

Mr. Kirchner serves as the wheels to our organization, providing a “Swiss Army Knife” set of skills to utR. His business experiences help shape the business side of our company including day to day management, HR, finance, sales and marketing.
After reviewing data compiled from over 200 peer-reviewed papers, utR Biotech has expressions of interest to participate in concept studies from the following well-respected researchers:

**Dr. Paul Fernyhough**
Dr. Fernyhough has researched & patented potential treatments for diabetic neuropathy. He currently resides in Winnipeg, Manitoba where he is the Director - Division of Neurodegenerative Disorders at the St. Boniface Hospital Research Centre & Professor, Dept. of Pharmacology & Therapeutics, University of Manitoba, Faculty of Medicine.

Dr. Fernyhough will be conducting two separate studies for utR Biotech. Block one involves a design space for insulin and the novel peptide concentrations in mice, followed by the result to be used in a larger study to examine neuropathy, some biological data analysis, as well as detection of microcirculation and other effects.

**Dr. Vernon Dolinski**
Dr. Dolinski’s research is focused on the mechanisms that predispose youth for the development of obesity, diabetes & related cardiovascular disorders. He is an Associate Professor at the Department of Pharmacology & Therapeutics within the Children’s Hospital Research Institute of Manitoba.

For utR Biotech, Dr. Dolinski will be performing cardiovascular disease studies in mice to determine if the novel peptide reduces, minimizes or delays disease onset.

**Dr. Sabine Kuss**
Dr. Sabine Kuss is an Assistant Professor at the University Of Manitoba, Faculty of Science, Department of Chemistry. Her research focuses on electrochemistry & its application to biological systems in the fields of endocrinological diseases, antibiotic drug resistance in pathogens, mitochondrial dysfunctions and cancer development.

With utR, Dr. Kuss will be looking at the interactions between the novel peptide and it’s putative receptors GPR146, which may help to elucidate the novel protein signalsome.
After reviewing data compiled from over 200 peer reviewed papers, utR Biotech has expressions of interest to participate in concept studies from the following well respected researchers:

**Dr. Benedict Albensi**
Dr. Albensi sits as the current Manitoba Dementia Research Chair. His research is centered around the biological basis of memory, impairment & target mechanisms for treatment to reverse or repair a variety of conditions such as Alzheimer’s disease, stroke, head trauma. He is a Professor - Department of Pharmacology & Therapeutics, University of Manitoba & Principal Investigator and Everett Endowment Fund Chair - Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre.

Dr. Albensi will be conducting a study in mice to examine the behavioral deficits & look to minimize, prevent, or delay the response for onset of Alzheimer’s Disease with a novel protein supplemented group. Pathological analysis will also be performed.

**Dr. Donald Miller**
Dr. Miller’s research is themed around Neuropharmacology, blood brain barrier function, & drug delivery with a focus on understanding the cellular mechanisms involved & changes in function with neurological conditions such as MS, neuro-AIDS, stroke, brain tumors & brain trauma as the BBB becomes compromised. Dr. Miller is a Professor - Department of Pharmacology & Therapeutics, Kleysen Institute for Advanced Medicine, University of Manitoba.

Dr. Miller will be conducting epithelial studies to examine upregulation & downregulation of some 20,000 genes using microarray analysis on primary diabetic cell lines relative to the control. The data will be analyzed to aid in mapping out the novel protein signalsome forming the backbone of IP around our product.

**Dr. Suresh Mishra**
Dr. Mishra’s research is centered around PTMs & their regulation of protein functions with specific study in pathways to type 2 diabetes, insulin resistance and mitochondrial dysfunction, changes in protein function and protein-protein interactions. Dr. Mishra patented mouse models for studying diabetes with cancer and diabetes with NAFL. Dr. Mishra is an Associate Professor, Department of Internal Medicine, University of Manitoba.

Dr. Mishra will be working with utR Biotech to study our protein in diabetic/cancer mice and diabetic/NAFLD mice and look to minimize, prevent, or delay the response for onset of cancer and liver disease with a novel protein supplemented group.
Current State of Insulin Therapeutics

- Global market for **insulin** is dominated by Novo Nordisk, Eli Lily and Sanofi Pasteur
  - $24 billion in the US alone (2016)
  - Expected to increase to $48 billion by 2025 based on the current rate of increase of diabetes
- Current formulations have a shelf life of 3 months at 2-8°C
- Manufactured using old technologies with low product yields – drives the cost up for the end user
- Estimates are that there will be an ongoing shortage of insulin supply for the next decade
- Patients are “stretching” their medications in order to afford them, putting their health at increased risk
- Over 1.4 trillion USD/year currently spent on treating the associated symptoms and diseases of T1D and T2D globally

All commercial insulin products are insulin/insulin NPH or analogues and exclude a critical component of the pro-insulin molecule

They do not prevent the typical symptoms of peripheral neuropathy, retinopathy, CVD, NAFLD, and reduced microvasculation experienced by a large majority of Type I diabetes patients

ACCISS has suggested governments produce native insulin rather than analogues to target lower to middle income people. We plan on following their guidelines, alongside a lyophilized formula and inclusion of a special protein
Market Opportunities (US)

2016 Insulin Sales in US (% of 24 billion)

- Novo Nordisk: 52%
- Eli Lily: 23%
- Sanofi Pasteur: 14%
- Others: 11%

Projected 2025 Insulin Sales in US (% of 48 billion)

- Novo Nordisk: 52%
- Eli Lily: 23%
- Sanofi Pasteur: 14%
- Others: 10.5%
- utR Biotech: 0.5%

0.5% of Global Market Share of “Others” = 525 Million In Sales
Specialties of utR Biotech

- Concept studies & research
- Pre-clinical study design (Toxicology & pK)
- Process development, purification & optimization of recombinant and native proteins
- Development and optimization of cell cultures (ie. Yeast, CHO, E. coli)
- Scale-up and tech transfer
- Analytical development
- Process qualification & validation
- Formulation development & stability
- Project Management of Biopharmaceuticals
Problems In Diabetes Treatments

- Global Insulin shortage for type 1 and 2 diabetes
- For T1D, insulin solves the problem of helping glucose transport, yet the following symptoms still persist:
  - Lack of microcirculation leading to neuropathy
  - Patients are reducing insulin intake to manage costs
  - Increased frequency for developing CVD, AD, & Cancer
  - Treating complications costs hundreds of billions $

There is currently no product on the market to address diabetes complications or rising insulin cost, only “manage” the disease
Technology & Product

• Cheaper insulin due to the use of a high output expression system (12 to 20 g/L) for proinsulin
• Addition of a novel protein to reduce/minimize the usual side effects associated with T1D (AD, cancer, CVD, neuropathies, NASH and NAFLD, lack of microcirculation)
• Lyophilized formula with a 24 month shelf life compared to 3 currently, which in turn will help reduce pharmacy dispensing fees
• Novel enzyme digestion scheme to minimize purification costs, lower end product costs
## Additive Functions

<table>
<thead>
<tr>
<th>Function In Vivo*</th>
<th>Negative Effects based on Absence In Vivo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintains nerve function and prevents neuropathy</td>
<td>Peripheral neuropathy, pain, inflammation, amputation</td>
</tr>
<tr>
<td>Preserves and improves residual B-cell function</td>
<td>Reduced immune function</td>
</tr>
<tr>
<td>Maintains intracellular signalling</td>
<td>Fatigue, sickness</td>
</tr>
<tr>
<td>Positive influence on endothelial nitric oxide synthase (eNOS) which prevents microvascular complications</td>
<td>Reduced blood flow, tissue death, potential links to CVD, AD, Cancer, Liver Disease</td>
</tr>
<tr>
<td>Promotes transcription of genes encoding RNA</td>
<td>Reduced cellular functions, reduced QOL</td>
</tr>
<tr>
<td>Reduces inflammation</td>
<td>Joint pain, fatigue, reduced QOL</td>
</tr>
<tr>
<td>Improves blood flow into tissues (skeletal muscle)</td>
<td>Chest pain, breathing issues, pain, inflammation</td>
</tr>
<tr>
<td>Protects against apoptosis of renal cells</td>
<td>Reduced kidney function, decreased urinary health, pain, discomfort</td>
</tr>
</tbody>
</table>

* More functions to be experimentally confirmed
Future State with utR Biotech

• Decreased manufacturing costs (~30-70%) based on a newly developed cell culture system using *Pichia* yeast genetically modified with MeOH genes replaced with Glc genes.
  • Our CMO has validated an expression system for this cell line to reduce the overall culture time and boost expression levels
  • Proinsulin excreted extra-cellularly making the purification process less laborious
  • Live cell based enzyme cocktail for cleaving of Proinsulin
• Inclusion of special protein
• Lyophilized formulation to extend shelf life and decrease dispensing fees passed on to the end user (cost reduction)
  • The drug substance will include 3 forms of insulin and novel protein combinations giving the end user flexibility in choosing the formulation best suited for their needs.
  • Subcutaneous and sublingual (partnership opportunity) administrations
• Target markets are for veterinary use (utRinsulin A) and US low to middle income human patient use (utRinsulin H). Former to generate revenue to lower future dilution
utR Development Path

Investment

Concept Studies (2019-2022)
Patents – Peptide treatment to delay, reduce, treat Type 1 complications & secondary diseases (Expect 6 to 8 patents)

CMO Development Work for product & enzyme cocktail (2022-2023)
Patent – Development of cell system to digest pro-insulin
Winnipeg Offices & Lab & Research Establishment (2021-2022)

Preclinical (2023)
Patent – Lyophilisation & resuspension with two different pH systems
Patent – Development of sublingual insulin delivery

Clinical Phase 1 (2024)
Veterinary Target Animal Safety (2024)

Clinical Phase 2 (2025)
Go public option

Series A
Series B
Development Path of Product (Post Concept Studies)

Concept study research on our peptide is expected to start in 2020 and complete within 24 to 36 months of initial funding.
# Employment for Staffing Office

<table>
<thead>
<tr>
<th>Position</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEO/CSO</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>VP R&amp;D</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>VP Sales/Marketing</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CFO</td>
<td>*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Regulatory</td>
<td>-</td>
<td>X</td>
<td>X</td>
<td>2X</td>
<td>2X</td>
<td>2X</td>
</tr>
<tr>
<td>Biostatistician</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>QA Associates</td>
<td>-</td>
<td>X</td>
<td>X</td>
<td>2X</td>
<td>2X</td>
<td>2X</td>
</tr>
<tr>
<td>Legal Associate</td>
<td>*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Scientists</td>
<td>5X*</td>
<td>5X*</td>
<td>5X*</td>
<td>3X</td>
<td>3X</td>
<td>3X</td>
</tr>
<tr>
<td>Clinical Associates</td>
<td>-</td>
<td>2X</td>
<td>2X</td>
<td>2X</td>
<td>2X</td>
<td>2X</td>
</tr>
<tr>
<td>Totals</td>
<td>9</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
</tr>
</tbody>
</table>

*Externally contracted*
# Financial Investment

<table>
<thead>
<tr>
<th>Category</th>
<th>2019-2022</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preclinical Research &amp; Patents – Peptides (24 Months)</td>
<td>2.2*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Process Development/Preclinical Supply</td>
<td>-</td>
<td>3.2</td>
<td>5.9</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Process Development for Enzyme Cocktail</td>
<td>-</td>
<td>3.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preclinical</td>
<td>-</td>
<td>-</td>
<td>0.32</td>
<td>2.4</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TAS for Vet Market</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Clinical Supply (Phase 1,2)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Clinical Studies (Phase 1,2)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Salaries</td>
<td>-</td>
<td>1.75</td>
<td>1.75</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Legal</td>
<td>-</td>
<td>0.25</td>
<td>0.25</td>
<td>2.0</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Travel/Training</td>
<td>-</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Other (Lease, IT, lab setup/supply)</td>
<td>-</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
</tr>
<tr>
<td><strong>Totals (millions $USD)</strong></td>
<td>2.2*</td>
<td>9.60</td>
<td>9.62</td>
<td>9.70</td>
<td>8.15</td>
<td>8.15</td>
</tr>
</tbody>
</table>

*Possibility of matched MITACS matched grants
Thank you for considering utR Biotech. Many aspects of market analysis, white paper of comparators of failed products and why they failed discussed in business plan as per below.

For more information, a copy of our 128 page business plan with financials (209 references to date), or to learn more about our company, please contact us at:

utR Biotech
100 Innovation Drive, Winnipeg MB, R3T 5A6
David Petch, CEO, Founder
1-204-333-7862
dpetch@utrbiotech.com

Lyle Kirchner, VP Global Sales & Marketing, Founder
1-807-407-6581
lkirchner@utrbiotech.com